Walter Capone

Walter Capone General Information

Biography

Mr. Walter Capone serves as Chief Executive Officer & President at Retinova Therapeutics. He served as Chief Business Officer at GeneCentric. He serves as Venture Partner at Boston Millennia Partners. Furthermore, he most recently served as CEO and President of the Multiple Myeloma Research Foundation (MMRF) and the Multiple Myeloma Research Consortium (MMRC), advancing industry, academic research, government agency, and patient community collaborations to drive breakthroughs for patients. The launch of the landmark CoMMpassSM Study, support in advancing six new myeloma therapies to market, and expansion in innovative academic/industry partnerships were among his numerous accomplishments. Prior to the MMRF, he had over 20 years of pharmaceutical and biotechnology leadership experience in Commercial Development, Operations, Finance, Marketing, and Sales in the United States and internationally at Progenics Pharmaceuticals, Trimeris Inc., Triangle Pharmaceuticals, Bristol-Myers Squibb, Wyeth, Cyanamid Benelux, and Lederle. In that time, he managed commercial drug product portfolios valued at over $500M; led or co-led the development, US and International launches as well as commercialization of 18 novel drugs including Fuzeon®, Emtriva®, Tequin®, Zerit®, Videx®, Maxipime® and Zosyn®; and managed over 30 other individual drug brands. He received his MBA from Columbia University Business School and BA from Brown University. He served as President & Chief Executive Officer at Multiple Myeloma Research Foundation.